Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Clinical trial NCT07608432 · RECRUITING

Trial details

NCT number: NCT07608432
Sponsor: Dyne Therapeutics
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Duchenne Muscular Dystrophy (DMD)Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD)DMD Muscular Dystrophies Muscular Dystrophy in Children Muscular Dystrophy, Duchenne Type Muscular Dystrophy, Duchenne and Becker Types Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)Genetic Disease, Inborn Genetic Disease, X-Linked Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Start date: 2026-06-01
Primary completion: 2030-12-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.